Form 4: ARS Pharmaceuticals Chief Legal Officer Alexander Fitzpatrick Reports Stock Transactions
SEC Form 4 Filing
Alexander Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, reports the acquisition and disposal of common stock and stock options.
Summary
- Alexander Fitzpatrick, the Chief Legal Officer of ARS Pharmaceuticals, reported transactions involving the company's stock on May 20, 2025.
- Fitzpatrick acquired 100,000 shares of common stock through the exercise of stock options at a price of $5.58 per share.
- He also disposed of 102,969 shares of common stock at a weighted average price of $14.0966, with prices ranging from $14.02 to $14.25.
- Following these transactions, Fitzpatrick beneficially owns 89,613 shares of common stock and holds options for 200,000 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company executives. It's a standard practice for publicly traded companies and their officers.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan. |
| January 1, 2025 | 25% of the shares subject to the option vested. |
| May 20, 2025 | Date of stock option exercise and stock sale transactions. |
| May 22, 2025 | Date of signature of the Form 4 filing. |
| January 1, 2034 | Expiration date of stock options. |
Keywords
ARS Pharmaceuticals, Alexander Fitzpatrick, stock options, common stock, Form 4, insider trading, SPRY, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.